FIVE-YEAR FINAL RESULTS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK/SECONDARY ACUTE MYELOID LEUKEMIA (AML) J.E. Lancet; T.L. Lin; D. Hogge; S.R. Solomon; G.J. Schiller; M.J. Wieduwilt; R. Martin; S. Faderl; Y. Chang; J.E. Cortes;